Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences has research collaboration with Trinity College Dublin to Investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is headquartered in La Jolla, California.
IPO Year:
Exchange: NASDAQ
Website: artelobio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/1/2021 | $4.00 | Buy | HC Wainwright & Co. |
SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Tamara A. Seymour to the Company's Board of Directors replacing John Liatos, who will continue in his role as Kintara's Senior Vice President of Business Development. "We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive," comm
LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appointment of Tamara A. Seymour, CPA, to the Company’s board of directors. “We are pleased to welcome Tamara to Artelo’s board of directors,” said Connie Matsui, Board Chair. “Tamara brings with her an impressive track record in corporate finance and capital markets, as well as extensive experience guiding biopharmaceutical and diagnostic companies from clinical stage to commercialization. We believe her advice a
LA JOLLA, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the appointment of Andrew Yates, Ph.D, as Senior Vice President and Chief Scientific Officer. Dr. Yates is an experienced senior pharmaceutical executive, having served most recently at AstraZeneca, in significant roles across a number of functional areas including development and commercial strategy, medical affairs, and business development. Notably, Dr. Yates has been extensively involved in the life-cycle managem
LA JOLLA, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the appointment of drug discovery and development veteran Gregory R. Reyes, M.D., Ph.D. to the Company’s Board of Directors, effective November 30, 2020. “Dr. Reyes’ expert role and track record in taking small molecules and biologics through the development process make him an ideal addition for the next phase of Artelo’s advancement,” commented Connie Matsui, chairperson of Artelo’s Board of Directors. “We a
HC Wainwright & Co. initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $4.00
LADENBURG THALM/SH SH initiated coverage of Artelo Biosciences with a rating of Buy
Ladenburg Thalmann initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $7.00
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
10-Q - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
S-8 - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
10-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
DEF 14A - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
DEFA14A - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
10-Q - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
SC 13G - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
SC 13G - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
SOLANA BEACH, Caif., May 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the three months ended March 31, 2025. Business Highlights: ART26.12: The first selective fatty acid binding protein 5 (FABP5) inhibitor to enter clinical trials completed enrollment of its Phase I safety study in healthy volunteers. Data readout remains on track for the second quarter of 2025.Newly published peer-reviewed
SOLANA BEACH, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Myles Osborn, Lead Medicinal Chemist at Artelo Biosciences, will be presenting at 12:30pm BST on April 3, 2025 during the 4th ACE Drug Discovery Summit being held at The Insurance Hall, London, UK. In the course of the presentation, titled "Comparative Multi-Omics to Interrogate Consensus Mechanisms of FABP5i Across Diverse Indications," Mr. Osborn will discuss an analysis of multiple datasets across
SOLANA BEACH, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the fiscal year ended December 31, 2024. Business Highlights: ART26.12: Phase I study is on track for completion in Q2 2025.ART27.13: Initial data from the Phase 2 CAReS trial anticipated by the end of Q2 2025.ART12.11: Substantial progress has been made toward initiation of human studies with an oral solid dosage form
SOLANA BEACH, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced nonclinical results on ART12.11, its proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). The findings were presented by Professor Saoirse O'Sullivan, Vice President of Translational Science at Artelo Biosciences, at the International Medical Cannabis Conference (IMCCB-25), held February 13-14, 2025, at the University of Bern, Switzerland. Professor O'Sullivan'
SOLANA BEACH, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that it will be presenting data on ART12.11, a proprietary cocrystal composed of cannabidiol (CBD) and tetramethylpyrazine (TMP), at the International Medical Cannabis Conference (IMCCB-25) held at the University of Bern, Switzerland February 13-14, 2025. Professor Saoirse O'Sullivan, Vice President Translational Science at Artelo Biosciences, is scheduled to deliver a presentation entitled, "
The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects Initial safety and pharmacokinetic data expected during the first half 2025 SOLANA BEACH, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, or dermatologic and neurological conditions, today announced the completed safety review of the first cohort of eight healthy volunteers in the Company's Phase 1 study of ART26.12. Progression to the next cohort marks a major milestone in the development of Fatty Acid Binding Prote
SOLANA BEACH, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, and neurological conditions, today announced the presentation of preliminary data on ART27.13, the Company's benzimidazole derivative, being studied for cancer-related anorexia. The data was presented by the Principal Investigator, Professor Barry J. A. Laird, Chair of Palliative and Supportive Care, University of Edinburgh and Consultant Physician in Palliative Medicine, Edinburgh Cancer Centre, at the 17th International Conference on Sa
SOLANA BEACH, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological and neurological conditions, today announced that Professor Saoirse O'Sullivan, Vice President of Translational Sciences at Artelo, will be presenting at the 7th Cannabinoid-Derived Drug Development Summit. The event will take place November 18-20, 2024, at the Wyndham Beacon Hill Hotel in Boston, MA. Key data from Artelo's development programs will be highlighted in three separate sessions titled: Fatty Acid-Binding Protein 5 (FAB
SOLANA BEACH, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, announced new data being presented today on ART26.12, Artelo's lead clinical Fatty Acid Binding Protein 5 (FABP5) inhibitor, in osteoarthritis (OA) pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium in New York. This evidence adds OA pain to the list of pain types such as neuropathic and cancer bone pain where ART26.12 has shown potential as an analgesic with a novel mechanism of action.
SOLANA BEACH, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported its financial and operating results for the three months ended September 30, 2024, and provided a business update. "With the ongoing, rapid progress of our pipeline, we anticipate multiple clinical readouts over the next 15 months," stated Gregory D. Gorgas, President and CEO of Artelo Biosciences. "Starting with ART26.12, our promising Fatty Acid Binding Protein 5 (FABP5) inhibitor drug candida